Want to see TSE:KITS full AI Analyst Report?
Top Page
Kits Eyecare
(TSX:KITS)
Select Model
Select Model
Rating:70Outperform
Price Target:
C$18.00
▲(13.85% Upside)
Action:Upgraded
Date:08/10/26
The score is driven primarily by improving financial performance (profitability inflection, positive free cash flow, and a de-risked balance sheet) and a positive earnings update with supportive guidance and strong customer/revenue quality indicators. Offsetting these strengths are a demanding valuation (high P/E, no dividend support) and only moderate technical strength given the stock remains below its 200-day average.
Positive Factors
Revenue scale and profitability inflection
Sustained revenue scaling and the shift from losses to positive earnings indicate improving operating leverage. Continued margin gains could strengthen the model as sales expand, although profitability is not yet deeply established.
Negative Factors
Thin net profitability cushion
Net profitability remains modest relative to revenue, leaving limited protection if customer demand weakens or operating costs rise. The business must sustain gross-margin improvements and control expenses to convert growth into durable returns.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue scale and profitability inflection
Sustained revenue scaling and the shift from losses to positive earnings indicate improving operating leverage. Continued margin gains could strengthen the model as sales expand, although profitability is not yet deeply established.
Read all positive factors
Kits Eyecare (KITS) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$517.23M
Dividend YieldN/A
Average Volume (3M)85.42K
Price to Earnings (P/E)89.6
Beta (1Y)1.44
Revenue Growth21.49%
EPS Growth42.38%
CountryCA
Employees176
SectorConsumer Cyclical
Sector Strength84
IndustrySpecialty Retail
Share Statistics
EPS (TTM)0.17
Shares Outstanding34,006,240
10 Day Avg. Volume85,440
30 Day Avg. Volume85,421
Financial Highlights & Ratios
PEG Ratio-103.72
Price to Book (P/B)9.43
Price to Sales (P/S)2.90
P/FCF Ratio51.86
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$24.17Price Target Upside52.86% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)0.18
Revenue Forecast (FY)C$244.12M
Kits Eyecare Business Overview & Revenue Model
Company Description
Kits Eyecare Ltd. operates an online vision care platform that serves customers throughout the United States and Canada. The company produces its own range of KITS-branded products, encompassing progressive and contact lenses, as well as spectacle...
How the Company Makes Money
KITS makes money mainly by selling vision products directly to customers online, capturing retail revenue without relying primarily on third-party brick-and-mortar optical stores. Its key revenue streams include: (1) Prescription eyeglasses and fr...
Kits Eyecare Earnings Call Summary
Earnings Call Date:Aug 05, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Nov 11, 2026
Earnings Call Sentiment Positive
The call highlights multiple substantial operational and financial achievements — record operating cash flow, return to net income, continued adjusted EBITDA positivity, strong glasses growth (high single‑digit to double‑digit contributions), expanding gross margin, and a strengthened balance sheet with no debt — while acknowledging deliberate near‑term tradeoffs: higher marketing to acquire higher‑value glasses customers, modest fulfillment pressure from fuel surcharges, and some elevated G&A timing effects. Management frames the negatives as intentional investments that should drive higher lifetime value and margin over time.Positive Updates
Record Revenue and Strong First Half Performance
Q2 revenue of $58.4 million (reported up 7.8% year‑over‑year and 17.9% as stated), with first half revenue of $115.9 million, up 20.5% year‑over‑year.
Negative Updates
Near‑term Revenue Growth Deceleration from Q1 Pace
Management acknowledged total revenue growth decelerated from Q1 as a deliberate trade‑off for shifting acquisition and merchandising toward higher‑value glasses customers.
Read all updates
Q2-2026 Updates
Positive
Negative
Record Revenue and Strong First Half Performance
Q2 revenue of $58.4 million (reported up 7.8% year‑over‑year and 17.9% as stated), with first half revenue of $115.9 million, up 20.5% year‑over‑year.
Read all positive updates
Company Guidance
For Q3 management guided revenue of C$62–64 million and an adjusted EBITDA margin of 4–6%, saying it expects continued momentum in the back half as it rebalances acquisition toward contact lenses while keeping glasses momentum; they plan marketing at a normalized mid‑teen percent of revenue (Q2 marketing was 17.4%), and highlighted that the company enters H2 with C$27.4M cash, zero debt and roughly C$42.4M of accessible liquidity, supported by record operating cash flow of C$7.8M (≈13% of Q2 revenue), free cash flow of C$6.4M, H1 constant‑currency growth of ~22%, an Autoship annuity of C$24.6M, repeat customers contributing 65.5% of revenue, AOV of C$213 (up 15.8%), and glasses now ~19% of revenue (C$11.1M).Kits Eyecare Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
86
Very Positive
Cash Flow
74
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 222.18M | 202.46M | 159.34M | 120.51M | 91.64M | 82.40M |
| Gross Profit | 81.88M | 71.28M | 53.65M | 40.79M | 29.25M | 20.89M |
| EBITDA | 11.27M | 10.64M | 8.31M | 1.86M | -721.00K | -14.25M |
| Net Income | 5.63M | 3.11M | 3.12M | -2.21M | -4.55M | -14.62M |
Balance Sheet | ||||||
| Total Assets | 109.71M | 112.96M | 103.02M | 87.64M | 93.86M | 90.94M |
| Cash, Cash Equivalents and Short-Term Investments | 27.39M | 33.67M | 19.27M | 16.04M | 18.79M | 20.50M |
| Total Debt | 5.15M | 15.82M | 12.60M | 15.39M | 19.44M | 22.94M |
| Total Liabilities | 36.91M | 50.65M | 45.13M | 36.20M | 40.16M | 36.16M |
| Stockholders Equity | 72.80M | 62.31M | 57.89M | 51.45M | 53.71M | 54.78M |
Cash Flow | ||||||
| Free Cash Flow | 10.62M | 11.33M | 9.88M | 1.84M | 4.42M | -23.09M |
| Operating Cash Flow | 12.18M | 11.46M | 13.04M | 2.40M | 4.68M | -19.46M |
| Investing Cash Flow | -3.03M | -5.13M | -3.15M | -563.00K | -258.00K | -3.63M |
| Financing Cash Flow | 426.00K | 3.47M | -5.02M | -5.07M | -5.13M | 41.48M |
Kits Eyecare Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | C$75.29B | 17.29 | 19.91% | 1.02% | 11.59% | 26.58% | |
70 Outperform | C$517.23M | 89.63 | 8.44% | ― | 21.49% | 42.38% | |
69 Neutral | C$1.71B | 10.79 | 12.76% | 5.88% | -0.15% | -2.29% | |
63 Neutral | C$10.07B | 15.00 | 11.53% | 3.42% | 1.05% | -6.66% | |
63 Neutral | C$1.26B | 12.96 | 110.16% | 2.71% | 5.62% | 7.18% | |
61 Neutral | $18.38B | 12.79 | -2.54% | 3.03% | 1.52% | -15.83% | |
44 Neutral | C$14.35M | -44.44 | 3.76% | ― | 22.89% | 25.00% |
* Consumer Cyclical Sector Average
TSE:KITS
Kits Eyecare
15.21
-1.45
-8.70%
TSE:ATD
Alimentation Couche-Tard Inc
82.00
8.45
11.49%
TSE:LNF
Leon's Furniture
24.81
-3.09
-11.07%
TSE:CTC
Canadian Tire
210.00
-27.60
-11.62%
TSE:ECOM
Emerge Commerce Ltd
0.08
>-0.01
-11.11%
TSE:PET
Pet Valu Holdings Ltd.
18.79
-19.39
-50.79%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.